Free Listing
Q » What are the challenges in biosimilars be optimized in developing countries?
31 Oct, 2025
|
⋮
A » Developing countries face challenges in biosimilar optimization, including regulatory hurdles, limited infrastructure, and a lack of skilled professionals. Cost constraints and intellectual property issues further complicate access and innovation. Additionally, ensuring quality, safety, and efficacy standards comparable to original biologics is critical, requiring robust pharmacovigilance. Collaborations with international organizations and investment in local capacity building are essential for overcoming these obstacles and improving healthcare outcomes.
31 Oct, 2025
|
⋮
Still curious? Ask our experts.
Chat with our AI personalities
I'm here to listen you
Taiga
Keep pushing forward.
Always by your side.
Blake
Play the long game.
Vivi
Focus on what matters.
Rafa
Keep asking, keep learning.
Verified
